Ascendis Pharma A/S (NASDAQ:ASND) Expected to Post Quarterly Sales of $2.58 Million

Analysts forecast that Ascendis Pharma A/S (NASDAQ:ASND) will report sales of $2.58 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Ascendis Pharma A/S’s earnings. The lowest sales estimate is $2.42 million and the highest is $2.84 million. Ascendis Pharma A/S reported sales of $3.61 million in the same quarter last year, which indicates a negative year over year growth rate of 28.5%. The company is expected to issue its next quarterly earnings report on Wednesday, August 26th.

According to Zacks, analysts expect that Ascendis Pharma A/S will report full-year sales of $10.13 million for the current fiscal year, with estimates ranging from $2.42 million to $15.15 million. For the next fiscal year, analysts anticipate that the firm will post sales of $80.44 million, with estimates ranging from $40.00 million to $130.43 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Tuesday, May 19th. The biotechnology company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.43) by $0.11. Ascendis Pharma A/S had a negative net margin of 2,231.94% and a negative return on equity of 36.56%. The business had revenue of $2.45 million for the quarter, compared to analysts’ expectations of $2.66 million.

Several equities research analysts recently weighed in on the stock. Credit Suisse Group increased their price objective on shares of Ascendis Pharma A/S from $149.00 to $154.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 20th. BidaskClub upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Friday. Bank of America reiterated a “buy” rating and set a $145.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, March 27th. Wedbush assumed coverage on shares of Ascendis Pharma A/S in a research note on Friday. They set a “buy” rating and a $188.00 price objective on the stock. Finally, Zacks Investment Research lowered shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Thursday, April 2nd. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Ascendis Pharma A/S presently has a consensus rating of “Buy” and an average target price of $168.50.

Several large investors have recently made changes to their positions in ASND. Vivo Capital LLC acquired a new position in shares of Ascendis Pharma A/S during the first quarter valued at approximately $225,574,000. Janus Henderson Group PLC increased its stake in shares of Ascendis Pharma A/S by 284.1% during the fourth quarter. Janus Henderson Group PLC now owns 1,253,004 shares of the biotechnology company’s stock valued at $174,318,000 after acquiring an additional 926,762 shares during the period. RA Capital Management L.P. increased its stake in shares of Ascendis Pharma A/S by 17.4% during the first quarter. RA Capital Management L.P. now owns 4,914,955 shares of the biotechnology company’s stock valued at $553,473,000 after acquiring an additional 729,613 shares during the period. Westfield Capital Management Co. LP increased its stake in shares of Ascendis Pharma A/S by 12.2% during the fourth quarter. Westfield Capital Management Co. LP now owns 1,260,756 shares of the biotechnology company’s stock valued at $175,396,000 after acquiring an additional 136,702 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter valued at approximately $18,658,000. Institutional investors own 99.96% of the company’s stock.

Shares of ASND stock traded down $2.91 during trading hours on Monday, hitting $145.21. 78,071 shares of the company were exchanged, compared to its average volume of 214,838. The stock has a market capitalization of $7.04 billion, a price-to-earnings ratio of -27.22 and a beta of 0.97. Ascendis Pharma A/S has a one year low of $90.06 and a one year high of $158.93. The business’s 50-day simple moving average is $143.34 and its two-hundred day simple moving average is $132.04. The company has a debt-to-equity ratio of 0.06, a quick ratio of 13.19 and a current ratio of 13.19.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Article: What does a hold rating mean?

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.